collection
MENU ▼
Read by QxMD icon Read
search

IBD

shared collection
196 papers 500 to 1000 followers
By Jeff Bank Internal Medicine R2 at the University of Utah
https://www.readbyqxmd.com/read/28631729/backwash-is-hogwash-the-clinical-significance-of-ileitis-in-ulcerative-colitis
#1
Deepa T Patil, Robert D Odze
No abstract text is available yet for this article.
June 20, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28506689/genetic-factors-interact-with-tobacco-smoke-to-modify-risk-for-inflammatory-bowel-disease-in-humans-and-mice
#2
Pankaj Yadav, David Ellinghaus, Gaëlle Rémy, Sandra Freitag-Wolf, Anabelle Cesaro, Frauke Degenhardt, Gabrielle Boucher, Myriam Delacre, Laurent Peyrin-Biroulet, Muriel Pichavant, John D Rioux, Philippe Gosset, Andre Franke, L Philip Schumm, Michael Krawczak, Mathias Chamaillard, Astrid Dempfle, Vibeke Andersen
BACKGROUND & AIMS: The role of tobacco smoke in the etiology of inflammatory bowel disease (IBD) is unclear. We investigated interactions between genes and smoking (gene-smoking interactions) that affect risk for Crohn's disease (CD) and ulcerative colitis (UC) in a case-only study of patients and in mouse models of IBD. METHODS: We used 55 immunochip-wide data sets that included 19,735 IBD cases (10,856 CD cases and 8879 UC cases) of known smoking status. We performed 3 meta-analyses each for CD, UC, and IBD (CD and UC combined), comparing data for never vs ever smokers, never vs current smokers, and never vs former smokers...
May 12, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28508869/multidisciplinary-team-based-approaches-to-ibd-management-how-might-one-stop-shopping-work-for-complex-ibd-care
#3
Chang Kyun Lee, Gil Y Melmed
No abstract text is available yet for this article.
June 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28417994/trends-in-epidemiology-of-pediatric-inflammatory-bowel-disease-in-canada-distributed-network-analysis-of-multiple-population-based-provincial-health-administrative-databases
#4
Eric I Benchimol, Charles N Bernstein, Alain Bitton, Matthew W Carroll, Harminder Singh, Anthony R Otley, Maria Vutcovici, Wael El-Matary, Geoffrey C Nguyen, Anne M Griffiths, David R Mack, Kevan Jacobson, Nassim Mojaverian, Divine Tanyingoh, Yunsong Cui, Zoann J Nugent, Janie Coulombe, Laura E Targownik, Jennifer L Jones, Desmond Leddin, Sanjay K Murthy, Gilaad G Kaplan
OBJECTIVES: The incidence of pediatric-onset inflammatory bowel disease (IBD) is increasing worldwide. We used population-based health administrative data to determine national Canadian IBD incidence, prevalence, and trends over time of childhood-onset IBD. METHODS: We identified children <16 years (y) diagnosed with IBD 1999-2010 from health administrative data in five provinces (Alberta, Manitoba, Nova Scotia, Ontario, Quebec), comprising 79.2% of the Canadian population...
April 18, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28400196/association-of-ribonuclease-t2-gene-polymorphisms-with-decreased-expression-and-clinical-characteristics-of-severity-in%C3%A2-crohn-s-disease
#5
Rivkah Gonsky, Phillip Fleshner, Richard L Deem, Eva Biener-Ramanujan, Dalin Li, Alka A Potdar, Janine Bilsborough, Shaohong Yang, Dermot P B McGovern, Stephan R Targan
BACKGROUND & AIMS: Variants in the tumor necrosis factor superfamily member 15 gene (TNFSF15, also called TL1A) have been associated with risk for inflammatory bowel disease (IBD). TL1A affects expression of multiple cytokines to promote mucosal inflammation. Little is known about the TL1A-response pathways that regulate cytokine expression. We investigated T-cell gene expression patterns to determine the mechanisms by which TL1A regulates cytokine production, and whether these associate with outcomes of patients with Crohn's disease (CD)...
April 9, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28323274/therapeutic-drug-monitoring-in-ibd-prospective-promise-unfulfilled
#6
Shail M Govani, Akbar K Waljee
No abstract text is available yet for this article.
May 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28274849/patient-age-sex-and-inflammatory-bowel-disease-phenotype-associate-with-course-of-primary-sclerosing-cholangitis
#7
Tobias J Weismüller, Palak J Trivedi, Annika Bergquist, Mohamad Imam, Henrike Lenzen, Cyriel Y Ponsioen, Kristian Holm, Daniel Gotthardt, Martti A Färkkilä, Hanns-Ulrich Marschall, Douglas Thorburn, Rinse K Weersma, Johan Fevery, Tobias Mueller, Olivier Chazouillères, Kornelius Schulze, Konstantinos N Lazaridis, Sven Almer, Stephen P Pereira, Cynthia Levy, Andrew Mason, Sigrid Naess, Christopher L Bowlus, Annarosa Floreani, Emina Halilbasic, Kidist K Yimam, Piotr Milkiewicz, Ulrich Beuers, Dep K Huynh, Albert Pares, Christine N Manser, George N Dalekos, Bertus Eksteen, Pietro Invernizzi, Christoph P Berg, Gabi I Kirchner, Christoph Sarrazin, Vincent Zimmer, Luca Fabris, Felix Braun, Marco Marzioni, Brian D Juran, Karouk Said, Christian Rupp, Kalle Jokelainen, Maria Benito de Valle, Francesca Saffioti, Angela Cheung, Michael Trauner, Christoph Schramm, Roger W Chapman, Tom H Karlsen, Erik Schrumpf, Christian P Strassburg, Michael P Manns, Keith D Lindor, Gideon M Hirschfield, Bettina E Hansen, Kirsten M Boberg
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of disease progression based on distinct clinical phenotypes in a large international cohort of patients with PSC. METHODS: We performed a retrospective outcome analysis of patients diagnosed with PSC from 1980 through 2010 at 37 centers in Europe, North America, and Australia. For each patient, we collected data on sex, clinician-reported age at and date of PSC and IBD diagnoses, phenotypes of IBD and PSC, and date and indication of IBD-related surgeries...
June 2017: Gastroenterology
https://www.readbyqxmd.com/read/28220781/therapeutic-drug-monitoring-in-ibd-the-new-standard-of-care-for-anti-tnf-therapy
#8
Konstantinos Papamichael, Adam S Cheifetz
No abstract text is available yet for this article.
May 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28195179/fostering-collaboration-through-creation-of-an-ibd-learning-health-system
#9
Lisa C Johnson, Gil Y Melmed, Eugene C Nelson, Megan M Holthoff, S Alandra Weaver, Tamara S Morgan, Corey A Siegel
No abstract text is available yet for this article.
March 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28147377/case-report-acute-flair-of-ulcerative-colitis-during-pregnancy-is-still-a-major-problem
#10
Marijana Protic, Srdjan Markovic, Dino Tarabar
Although severe flare of ulcerative colitis (UC) is uncommon, it significantly increases the risk of preterm delivery, low birth weight and other adverse fetal outcomes. It is critical to optimize aggressive medical treatment with both mother and fetal health. Here, we present a case of a 30-year-old woman with a severe flare of UC at the 16th gestational week. The diagnosis of extensive UC was established 8 years ago. From the time she was diagnosed, she had 5 moderate flares successfully treated with oral and topical mesalamine...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28071656/acg-clinical-guideline-preventive-care-in-inflammatory-bowel-disease
#11
REVIEW
Francis A Farraye, Gil Y Melmed, Gary R Lichtenstein, Sunanda V Kane
Recent data suggest that inflammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health maintenance issues need to be co-managed by both the gastroenterologist and primary care team. Gastroenterologists need to explicitly inform the primary care provider of the unique needs of the IBD patient, especially those on immunomodulators and biologics or being considered for such therapy...
February 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28117363/increased-risk-of-gallstone-disease-following-colectomy-for-ulcerative-colitis
#12
Anders Mark-Christensen, Søren Brandsborg, Søren Laurberg, Niels Johansen, Jørn Helmut Pachler, Ole Thorlacius-Ussing, Mie Dilling Kjær, Niels Qvist, Louise Preisler, Jens Hillingsø, Jacob Rosenberg, Peter Jepsen
OBJECTIVES: Biochemical studies suggest that patients who have had a colectomy or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) are at an increased risk of developing gallstone disease, but epidemiological studies are lacking. We evaluated the risk of gallstone disease following colectomy and IPAA. METHODS: Individuals who had a colectomy were identified from a national cohort of patients with ulcerative colitis (UC), and controls without colectomy were sampled from within the same cohort, matching on gender, calendar year, and year of birth...
March 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28045023/meta-analytic-bayesian-model-for-differentiating-intestinal-tuberculosis-from-crohn-s-disease
#13
REVIEW
Julajak Limsrivilai, Andrew B Shreiner, Ananya Pongpaibul, Charlie Laohapand, Rewat Boonanuwat, Nonthalee Pausawasdi, Supot Pongprasobchai, Sathaporn Manatsathit, Peter D R Higgins
OBJECTIVES: Distinguishing intestinal tuberculosis (ITB) from Crohn's disease (CD) is difficult, although studies have reported clinical, endoscopic, imaging, and laboratory findings that help to differentiate these two diseases. We aimed to produce estimates of the predictive power of these findings and construct a comprehensive model to predict the probability of ITB vs. CD. METHODS: A systematic literature search for studies differentiating ITB from CD was conducted in MEDLINE, PUBMED, and EMBASE from inception until September 2015...
March 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27914655/crohn-s-disease
#14
REVIEW
Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with increasing incidence worldwide. Crohn's disease might result from a complex interplay between genetic susceptibility, environmental factors, and altered gut microbiota, leading to dysregulated innate and adaptive immune responses. The typical clinical scenario is a young patient presenting with abdominal pain, chronic diarrhoea, weight loss, and fatigue. Assessment of disease extent and of prognostic factors for complications is paramount to guide therapeutic decisions...
April 29, 2017: Lancet
https://www.readbyqxmd.com/read/27914657/ulcerative-colitis
#15
REVIEW
Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel
Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings...
April 29, 2017: Lancet
https://www.readbyqxmd.com/read/27960091/inflammatory-bowel-disease-2017-innovations-and-changing-paradigms
#16
Jean-Frederic Colombel, Uma Mahadevan
No abstract text is available yet for this article.
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27714831/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active-inflammatory-bowel-disease-a-prospective-multicenter-observational-study
#17
A Stallmach, C Langbein, R Atreya, T Bruns, A Dignass, K Ende, J Hampe, F Hartmann, M F Neurath, J Maul, J C Preiss, R Schmelz, B Siegmund, H Schulze, N Teich, U von Arnim, D C Baumgart, C Schmidt
BACKGROUND: Vedolizumab, a monoclonal antibody targeting the α4β7-integrin, is effective in inducing and maintaining clinical remission in Crohn's disease and ulcerative colitis according to randomised clinical trials. AIM: To determine the long-term effectiveness of vedolizumab in a real-world clinical setting. METHODS: This observational registry assessed the clinical outcome in patients treated with vedolizumab for clinically active Crohn's disease (n = 67) or ulcerative colitis (n = 60)...
December 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27888668/inflammatory-bowel-disease-a-global-disease-that-needs-a%C3%A2-broader-ensemble-of-populations
#18
EDITORIAL
Andre Franke
No abstract text is available yet for this article.
January 2017: Gastroenterology
https://www.readbyqxmd.com/read/27660341/3rd-european-evidence-based-consensus-on-the-diagnosis-and-management-of-crohn-s-disease-2016-part-1-diagnosis-and-medical-management
#19
Fernando Gomollón, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James O Lindsay, Laurent Peyrin-Biroulet, Garret J Cullen, Marco Daperno, Torsten Kucharzik, Florian Rieder, Sven Almer, Alessandro Armuzzi, Marcus Harbord, Jost Langhorst, Miquel Sans, Yehuda Chowers, Gionata Fiorino, Pascal Juillerat, Gerassimos J Mantzaris, Fernando Rizzello, Stephan Vavricka, Paolo Gionchetti
This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn's disease. Surgical management as well as special situations including management of perianal Crohn's disease of this ECCO Consensus are covered in a subsequent second paper [Gionchetti et al JCC 2016]...
January 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27845055/is-stem-cell-therapy-ready-for-prime-time-in-treatment-of-inflammatory-bowel-diseases
#20
Christopher J Hawkey, Daniel W Hommes
Autologous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for patients with refractory Crohn's disease (CD) and fistulizing CD, respectively. Will these highly advanced techniques be available only for select patients, at specialized centers, or is further clinical development justified, with the aim of offering widespread, more definitive therapeutic options for often very difficult to treat disease? Patients with CD who are eligible for HSCT have typically been failed by most approved therapies, have undergone multiple surgeries, and have coped with years of disease activity and poor quality of life...
February 2017: Gastroenterology
label_collection
label_collection
2221
1
2
2016-11-17 06:06:23
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"